

# XRpro Sciences, Inc.

## Company Description:

XRpro Sciences, Inc. provides a unique platform for drug discovery and development services featuring high throughput ion channel assays for the pharmaceutical industry. The Company's proprietary advances in X-ray fluorescence provide measurements that would otherwise be difficult or impossible applying other readily available technologies. XRpro® technology directly measures the activity of a drug target, without the need for costly and artifact-causing chemical dyes or radiolabels.

High throughput XRpro® technology allows the performance of assays that were previously unavailable or unacceptably expensive when performed using other technologies. Significant advantages of XRpro® according to customers include the ability to perform measurements in challenging matrices, such as serum (blood), and the ability to conduct assays of non-electrogenic transporters.

For further information, please visit [www.xrpro.com](http://www.xrpro.com).

## Key Investment Considerations:

- *Growing interest in Ion Channel and Transporter assays for early drug development*
- *Significant technology advantages vs. competitors*
- *Changing paradigm at big Pharma to outsource early drug development and discovery*
- *Trend opens up acquisition growth opportunities and future consolidation in the sector*
- *Company has cash on hand of \$9 million*
- *Superior management team now in place and executing business strategy*

## Company History:

XRpro, formerly known as Caldera, was founded by Dr. Benjamin Warner in 2003. While at Los Alamos National Laboratory, at the request of the then director of the facility, Dr. Warner was charged with commercializing technologies developed at LANL.

During this process, Dr. Warner patented his improvement to x-ray fluorescence technology that allowed it to be used to measure nanograms of material. This improvement made x-ray fluorescence economically feasible to measure the chemical composition of pharmaceuticals.

The Company has evolved over the years from providing primarily analytical services to Government Agencies such as the National Institutes of Health and the Department of Defense to a unique platform for drug discovery and development services featuring high throughput ion channel assays targeted at the pharmaceutical industry.

## Company Management:

### *Tim Tyson, Chairman*

Mr. Tyson has 35 years of experience in the biopharmaceutical industry with Bristol-Myers, Glaxo, Glaxo Wellcome, GSK, Valeant and Aptuit. Mr. Tyson is currently Chairman of Aptuit, LC. He served as President and CEO of Valeant Pharmaceuticals International from 2003-2008. During this period, sales grew 69% and earnings increased 135%. Prior to joining Valeant, Mr. Tyson ran multiple divisions for GlaxoSmithKline and was a member of the Corporate Executive Team, reporting to the CEO. During his 14-year tenure at GlaxoSmithKline, he was President, Global Manufacturing and Supply and ran Glaxo Dermatology and Cerenex Pharmaceuticals. Mr. Tyson was also responsible for managing all sales and marketing for GlaxoWellcome's U.S. operations, where he launched 32 new products, eight of which reached sales of greater than \$1 billion.

### *Richie Cunningham, President and CEO*

Mr. Cunningham brings over 17 years of leadership experience in the healthcare industry. Most recently, leading a team at Boehringer-Ingelheim strategically focused on Sales Acceleration, Product Launch Effectiveness and Operational Excellence. Prior to Boehringer-Ingelheim, Mr. Cunningham was at Valeant Pharmaceuticals where he was a senior executive in the commercial organization leading sales, marketing and contracting activities. Mr. Cunningham began his career in healthcare at Premier Inc., a healthcare company that served as a group purchasing and service organization for over 1700 hospitals throughout

the nation. While at Premier he served as the Marketing Director at Premier Practice Management, a subsidiary and start-up company of Premier Inc. In addition to establishing his healthcare career and in parallel, Richie also excelled as a professional athlete in the NFL holding All-Pro honors as a placekicker for the Dallas Cowboys, then later the Carolina Panthers and Jacksonville Jaguars.

***Benjamin Warner, Ph.D., Founder and CSO***

Dr. Warner founded the company in 2003 following a successful career as a scientist at the Los Alamos National Laboratory in Los Alamos, New Mexico where he garnered numerous awards for his commercialization and patenting work, including the Distinguished Licensing Award, the Distinguished Entrepreneurial Award, the Distinguished Patent Award, and the Federal Laboratory Consortium Distinguished Service Award. He has a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology.

***Mark Korb, Chief Financial Officer***

Mark Korb has served as our Chief Financial Officer since August 14, 2013. Mr. Korb has over 20-years experience with high-growth companies and experience taking startup operations to the next level. Since July 2011, First South Africa Management, a company for which Mr. Korb has served as the Chief Financial Officer since January 2010 has been providing consulting services to us, including the financial expertise required of public companies. First South Africa Management provides financial management and strategic management services to various companies.